Oppenheimer Thinks Agile Therapeutics’ Stock is Going to Recover

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Agile Therapeutics (AGRXResearch Report), with a price target of $4.00. The company’s shares closed last Wednesday at $1.26, close to its 52-week low of $1.07.

According to TipRanks.com, Gershell is a 3-star analyst with an average return of 3.0% and a 37.5% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.

Currently, the analyst consensus on Agile Therapeutics is a Strong Buy with an average price target of $5.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.89 and a one-year low of $1.07. Currently, Agile Therapeutics has an average volume of 1.04M.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.